{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:37:40Z","timestamp":1787647060767,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0138348","type":"journal-article","created":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T14:00:29Z","timestamp":1444140029000},"page":"e0138348","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":62,"title":["A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18\u201340 Year Old Subjects with Diagnosed Atopic Dermatitis"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00316602","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Richard N","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinh V.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Mraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Gomez","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"von Bredow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"von Krempelhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Virgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaly","family":"Arndtz-Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Peter","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3201\/eid0504.990415","article-title":"Smallpox: Clinical and epidemiologic features","volume":"5","author":"DA Henderson","year":"1999","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"AW Artenstein","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1542\/peds.55.3.342","article-title":"Smallpox vaccination reactions, prophylaxis, and therapy of complications","volume":"55","author":"JA Goldstein","year":"1975","journal-title":"Pediatrics"},{"issue":"22","key":"ref4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":". Complications of smallpox vaccination, 1968","volume":"281","author":"JM Lane","year":"1969","journal-title":"N Engl J Med"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: Results of ten statewide surveys","volume":"122","author":"JM Lane","year":"1970","journal-title":"J Infect Dis"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1067\/mai.2002.128052","article-title":"Smallpox vaccination: Risk considerations for patients with atopic dermatitis","volume":"110","author":"RJ Engler","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/587668","article-title":"Severe eczema vaccinatum in a household contact of a smallpox vaccinee","volume":"46","author":"S Vora","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2006.02.006","article-title":"Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus","volume":"24","author":"MD Howell","year":"2006","journal-title":"Immunity"},{"issue":"5414","key":"ref9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bmj.2.5414.906","article-title":"Eczema Vaccinatum","author":"P Copeman","year":"1964","journal-title":"Br Med J"},{"key":"ref10","first-page":"22","article-title":"Cutaneous complications of mass vaccination against smallpox in South Wales 1962","volume":"50","author":"E Waddington","year":"1964","journal-title":"Trans St Johns Hosp Dermatolo Soc"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.288.15.1901","article-title":"Contact vaccinia-transmission of vaccinia from smallpox vaccination","volume":"288","author":"JM Neff","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2310\/6620.2007.06034","article-title":"A population-based survey of eczema prevalence in the United States","volume":"18","author":"JM Hanifin","year":"2007","journal-title":"Dermatitis"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-139-1-200307010-00006","article-title":"Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination","volume":"139","author":"AL Naleway","year":"2003","journal-title":"Ann Intern Med"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2133.2006.07372.x","article-title":"Remembering childhood atopic dermatitis as an adult: factors that influence recollection","volume":"155","author":"C Moberg","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"ref15","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"AR Kemper","year":"2002","journal-title":"Eff Clin Pract"},{"issue":"47","key":"ref16","first-page":"2386","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author&apos;s transl)","volume":"99","author":"H Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"issue":"5\u20136","key":"ref17","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author&apos;s transl)","volume":"167","author":"A Mayr","year":"1978","journal-title":"Zentralbl Bakteriol [B]"},{"issue":"1","key":"ref18","first-page":"6","article-title":"Passage history, properties, and use of attenuated vaccinia virus strain MVA","volume":"3","author":"A Mayr","year":"1975","journal-title":"Infection"},{"issue":"51","key":"ref19","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"SE Frey","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects","volume":"207","author":"RN Greenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"J Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"A von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara as a Smallpox Vaccine in People with atopic dermatitis","volume":"32","author":"F von Sonnenburg","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"KJ Stittelaar","year":"2005","journal-title":"J Virol"},{"issue":"6979","key":"ref25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"PL Earl","year":"2004","journal-title":"Nature"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI33940","article-title":"Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection","volume":"118","author":"C Samuelsson","year":"2008","journal-title":"J Clin Invest"},{"issue":"31","key":"ref27","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"PL Earl","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","article-title":"Evaluation of smallpox vaccines using variola neutralization","author":"IK Damon","year":"2009","journal-title":"J Gen Virol"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000245677","article-title":"Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis","volume":"195","author":"B Kunz","year":"1997","journal-title":"Dermatology"},{"key":"ref30","article-title":"Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An open-Label, Controlled Clinical Phase II Trial. OFID 2015 1\u201310","author":"E Overton","journal-title":"Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An open-Label, Controlled Clinical Phase II Trial. OFID 2015 1\u201310"},{"issue":"9352","key":"ref31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0140-6736(03)12193-9","article-title":"Atopic Dermatitis","volume":"361","author":"DY Leung","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/000155501750376294","article-title":"Clinical features of atopic dermatitis at two years of age: a prospective, population-based case-control study","volume":"81","author":"M Boehme","year":"2001","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3346\/jkms.2010.25.12.1828","article-title":"Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area, Korea","volume":"25","author":"M Kim","year":"2010","journal-title":"J Korean Med Sci"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"MK Arness","year":"2004","journal-title":"Am J Epidemiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: The new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"A Nalca","year":"2010","journal-title":"Drug Design Development and Therapy"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"e54407","DOI":"10.1371\/journal.pone.0054407","article-title":"Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review","volume":"8","author":"ML Elizaga","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1378\/chest.125.5.1877","article-title":"Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance","volume":"125","author":"C Roongsritong","year":"2004","journal-title":"Chest"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jaci.2007.08.004","article-title":"Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation","volume":"120","author":"JE Scott","year":"2007","journal-title":"J Allergy Clin Immunol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0142802","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0138348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T14:53:41Z","timestamp":1653231221000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0138348"}},"subtitle":[],"editor":[{"given":"David Joseph","family":"Diemert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0138348","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725829881.793516074","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]}}}